Swiss Nuclides secures fresh capital
With the Series A financing round, Swiss Nuclides AG was able to raise CHF 2.6 million. Zurich-based Turos Capital AG and private investors were involved. This capital will be used to continue the preclinical and clinical development of the lead molecules.
The Aargau start-up develops solutions for personalized cancer diagnostics, prostate cancer and neuroendocrine tumors. This improves the use of positron emission tomography (PET). This reduces cancer diagnosis and radiation exposure for patients to a minimum. With this method, sugar metabolism processes are examined to identify changed tissue structures. The patients take glucose which is linked to a weakly radioactive tracer molecule.